Patent Application
20240336649
The instant application contains a Sequence Listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII file, created on Jul. 20, 2022, is named 20221025-021203-3.txt and is 3,901 bytes in size.
The transcription factor protein MYC forms a heterodimer with MAX in order to bind to the E-Box DNA sequence (CACGTG). The MYC/MAX protein complex is part of the basic-helix-loop-helix/leucine-zipper (bHLH/Lz) transcription factor family and initiates several cellular processes, including cell proliferation and survival. MAX, alternatively, can homodimerize, compete for the E-Box DNA binding site, and inhibit MYC/MAX-driven transcription. MYC/MAX and MAX/MAX, thus, have opposite activities, and MYC overexpression is observed in >50% of human cancers.
Promising strategies to inhibit the oncogenic MYC activity rely on stabilizing the natural MAX/MAX dimer or delivering protein analogs with a similar mechanism of action. The targeting of MYC with small molecules has largely remained elusive, mainly because the structure of MYC presents no binding pockets for small molecule ligands. Recent attempts to overcome the challenge of drugging MYC include a small molecule stabilizer of the MAX/MAX complex that inhibits the proliferation of several cancer cell lines and reduces tumor burden in murine cancer models. An alternate approach involves the artificial miniprotein Omomyc, a dominant-negative form of MYC that can compete for E-Box DNA binding and inhibit MYC/MAX dependent transcription, ultimately resulting in tumor growth inhibition in various mouse models of cancer.
Omomyc, like MYC and MAX, has to form dimeric complexes to be functional and bioactive. MYC, MAX, and Omomyc can interact with each other in different combinations. Upon delivery of a monomer to the cell, the dominating complex formed depends on the other proteins' cellular concentrations and is difficult to predict. The direct administration of defined and stable dimeric complexes would offer a superior degree of control over the concentration and composition of the bioactive dimer inhibitor, in addition to a potentially higher structural stability.
Preparing homogeneous, stable, well-defined protein-protein conjugates can be a challenge. Chemical synthesis approaches to generate covalently linked multimeric proteins have been mainly focused on preparing ubiquitinylated or sumoylated proteins. These strategies relied on chemical ligation or chemoenzymatic workflows, requiring the incorporation of unnatural amino acids or engineered recognition sequences, respectively. In addition, ligation based strategies to prepare covalently linked HIV protease heterodimers have been reported with the aim to study asymmetric mutations of this enzyme dimer. Previous dimerization strategies of MYC/MAX analogs relied on either disulfide formation at the C-terminus of the leucine zipper region of the transcription factor analogs or the formation of oxime and thioester linkages between MYC and MAX or between MAX and MAX. While these defined dimers enabled DNA-binding studies, the reported strategies relied on dovetails with low chemical stability in a biological milieu, making them unsuitable for bioactivity studies in vivo. Accordingly, there is a need for biologically stable dimers of MYC, MAX, and Omomyc.
The present disclosure provides, inter alia, a covalent protein dimer, or a pharmaceutically acceptable salt thereof, comprising: a first polypeptide comprising a C-terminus and an N-terminus, wherein the first polypeptide comprises a degree of identity of at least 85% with respect to SEQ ID NO: 1, 2, or 3; a second polypeptide comprising a C-terminus and an N-terminus, wherein the second polypeptide comprises a degree of identity of at least 85% with respect to SEQ ID NO: 1, 2, or 3; and a linker covalently linking the C-terminus of the first polypeptide to the C-terminus of the second polypeptide.
In another aspect, the disclosure provides a covalent protein dimer, or a pharmaceutically acceptable salt thereof, having a structure according to Formula (I):
In an embodiment, the covalent protein dimer has a structure according to Formula (Ib):
In another aspect, the disclosure provides a covalent protein dimer, or a pharmaceutically acceptable salt thereof, having a structure according to Formula (II):
In some embodiments, the covalent protein dimer has a structure according to Formula (IIb):
In another aspect, the disclosure provides a pharmaceutical composition comprising a covalent protein dimer of the disclosure and a pharmaceutically acceptable carrier. In another aspect, the disclosure provides a method of treating a disease or disorder characterized by MYC dysregulation in a subject in need thereof, the method comprising administering to the subject a covalent protein dimer of the disclosure. In an embodiment, the disease or disorder is cancer. In another aspect, the disclosure provides a method of making a covalent protein dimer of the disclosure.
Listed below are definitions of various terms used to describe the compounds and compositions disclosed herein. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.
Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, and peptide chemistry are those well-known and commonly employed in the art.
As used herein, the articles “a” and “an” refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element. Furthermore, use of the term “including” as well as other forms, such as “include,” “includes,” and “included,” is not limiting.
As used herein, the term “about” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. As used herein when referring to a measurable value such as an amount, a temporal duration, and the like, the term “about” is meant to encompass variations of ±20% or ±10%, including ±5%, ±1%, and ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
The term “administration” or the like as used herein refers to the providing a therapeutic agent to a subject. Multiple techniques of administering a therapeutic agent exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.
The term “treat,” “treated,” “treating,” or “treatment” includes the diminishment or alleviation of at least one symptom associated or caused by the state, disorder or disease being treated. In certain embodiments, the treatment comprises bringing into contact with a subject an effective amount of a covalent protein dimer of the disclosure for conditions related to cancer.
As used herein, the term “prevent” or “prevention” means no disorder or disease development if none had occurred, or no further disorder or disease development if there had already been development of the disorder or disease. Also considered is the ability of one to prevent some or all of the symptoms associated with the disorder or disease.
As used herein, the term “patient,” “individual,” or “subject” refers to a human or a non-human mammal. Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, canine, feline and marine mammals. Preferably, the patient, subject, or individual is human.
As used herein, the terms “effective amount,” “pharmaceutically effective amount,” and “therapeutically effective amount” refer to a nontoxic but sufficient amount of an agent to provide the desired biological result. That result may be reduction or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. An appropriate therapeutic amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
As used herein, the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
As used herein, the term “pharmaceutically acceptable salt” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. The phrase “pharmaceutically acceptable salt” is not limited to a mono, or 1:1, salt. For example, “pharmaceutically acceptable salt” also includes bis-salts, such as a bis-hydrochloride salt. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
As used herein, the term “composition” or “pharmaceutical composition” refers to a mixture of at least one compound useful within the disclosure with a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates administration of the compound to a patient or subject. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.
As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the disclosure within or to the patient such that it may perform its intended function. Typically, such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the disclosure, and not injurious to the patient. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations.
As used herein, “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the present disclosure, and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions. The “pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound disclosed herein. Other additional ingredients that may be included in the pharmaceutical compositions are known in the art and described, for example, in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.
As used herein, the term “MYC” refers to the protein MYC proto-oncogene encoded by the MYC gene, which is a member of the myc family of transcription factors, and has the following sequence:
As used herein, the term “MAX” refers to the transcription factor myc-associated factor X, which is encoded by the MAX gene and has the following sequence:
As used herein, the term “Omomyc” refers the artificial mini-protein that functions as a dominant-negative form of MYC and has the following sequence:
As used herein the nomenclature “protein-protein” (e.g., MAX-MAX or MYC-MAX) indicates a covalent dimer whereas the nomenclature “protein/protein” (e.g., MAX/MAX or MYC/MAX) indicates a non-covalent dimer.
As used herein, the term “alkyl,” by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain hydrocarbon having the number of carbon atoms designated (i.e., C1-C6 alkyl means an alkyl having one to six carbon atoms) and includes straight and branched chains. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert butyl, pentyl, neopentyl, and hexyl. Other examples of C1-C6 alkyl include ethyl, methyl, isopropyl, isobutyl, n-pentyl, and n-hexyl.
As used herein “heteroalkyl” refers to an alkyl group wherein one or more carbon atoms has been replaced with a heteroatom selected from O, S, or N, wherein alkyl is as defined herein.
As used herein, the term “alkoxy” refers to the group —O-alkyl, wherein alkyl is as defined herein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, t-butoxy and the like.
As used herein, the term “alkenyl” refers to a monovalent group derived from a hydrocarbon moiety containing, in certain embodiments, from two to six, or two to eight carbon atoms having at least one carbon-carbon double bond. The alkenyl group may or may not be the point of attachment to another group. The term “alkenyl” includes, but is not limited to, ethenyl, 1-propenyl, 1-butenyl, heptenyl, octenyl and the like.
As used herein, the term “halo” or “halogen” alone or as part of another substituent means, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom, preferably, fluorine, chlorine, or bromine, more preferably, fluorine or chlorine.
As used herein, the term “cycloalkyl” means a non-aromatic carbocyclic system that is fully or partially saturated having 1, 2 or 3 rings wherein such rings may be fused. The term “fused” means that a second ring is present (i.e., attached or formed) by having two adjacent atoms in common (i.e., shared) with the first ring. Cycloalkyl also includes bicyclic structures that may be bridged or spirocyclic in nature with each individual ring within the bicycle varying from 3-8 atoms. The term “cycloalkyl” includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [3.1.0] hexyl, spiro [3.3] heptanyl, and bicyclo [1.1.1] pentyl.
As used herein, the term “heterocyclyl” or “heterocycloalkyl” means a non-aromatic carbocyclic system containing 1, 2, 3 or 4 heteroatoms selected independently from N, O, and S and having 1, 2 or 3 rings wherein such rings may be fused, wherein fused is defined above. Heterocyclyl also includes bicyclic structures that may be bridged or spirocyclic in nature with each individual ring within the bicycle varying from 3-8 atoms, and containing 0, 1, or 2 N, O, or S atoms. Accordingly, the term “heterocyclyl” includes cyclic esters (i.e., lactones) and cyclic amides (i.e., lactams) and also specifically includes, but is not limited to, epoxidyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl (i.e., oxanyl), pyranyl, dioxanyl, aziridinyl, azetidinyl, pyrrolidinyl, 2-pyrrolidinonyl, 2,5-dihydro-1H-pyrrolyl, oxazolidinyl, thiazolidinyl, piperidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1,3-oxazinanyl, 1,3-thiazinanyl, 2-azabicyclo [2.1.1]hexanyl, 5-azabicyclo [2.1.1] hexanyl, 6-azabicyclo [3.1.1]heptanyl, 2-azabicyclo [2.2.1]heptanyl, 3-aza-bicyclo [3.1.1]heptanyl, 2-azabicyclo [3.1.1]heptanyl, 3-azabicyclo [3.1.0] hexanyl, 2-azabicyclo-[3.1.0]hexanyl, 3-azabicyclo [3.2.1]octanyl, 8-azabicyclo [3.2.1] octanyl, 3-oxa-7-azabicyclo [3.3.1]-nonanyl, 3-oxa-9-azabicyclo [3.3.1]nonanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6-oxa-3-aza-bicyclo [3.1.1]heptanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-6-azaspiro [3.3]heptanyl, 2-oxaspiro [3.3]-heptanyl, 2-oxaspiro[3.5]nonanyl, 3-oxaspiro [5.3]nonanyl, 2-azaspiro [3.3]heptane, 8-oxabicyclo[3.2.1]octanyl, 2,8-diazaspiro [4.5]decan-1-onyl, and 1,8-diazaspiro [4.5]decan-2-onyl.
As used herein, the term “aromatic” refers to a carbocycle or heterocycle with one or more polyunsaturated rings and having aromatic character, i.e., having (4n+2) delocalized π (pi) electrons, where n is an integer.
As used herein, the term “aryl” means an aromatic carbocyclic system containing 1, 2 or 3 rings, wherein such rings may be fused, wherein fused is defined above. If the rings are fused, one of the rings must be fully unsaturated and the fused ring(s) may be fully saturated, partially unsaturated or fully unsaturated. The term “aryl” includes, but is not limited to, phenyl, naphthyl, indanyl, and 1,2,3,4-tetrahydronaphthalenyl. In some embodiments, aryl groups have 6 carbon atoms. In some embodiments, aryl groups have from six to ten carbon atoms. In some embodiments, aryl groups have from six to sixteen carbon atoms.
As used herein, the term “heteroaryl” means an aromatic carbocyclic system containing 1, 2, 3, or 4 heteroatoms selected independently from N, O, and S and having 1, 2, or 3 rings wherein such rings may be fused, wherein fused is defined above. The term “heteroaryl” includes, but is not limited to, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazo [1,2-a]pyridinyl, pyrazolo [1,5-a]pyridinyl, 5,6,7,8-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydroquinolinyl, 6,7-dihydro-5H-cyclopenta [b]pyridinyl, 6,7-dihydro-5H-cyclo-penta[c]pyridinyl, 1,4,5,6-tetrahydrocyclopenta[c]pyrazolyl, 2,4,5,6-tetrahydrocyclopenta[c]-pyrazolyl, 5,6-dihydro-4H-pyrrolo [1,2-b]pyrazolyl, 6,7-dihydro-5H-pyrrolo [1,2-b][1,2,4]triazolyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, 4,5,6,7-tetrahydro-1H-indazolyl and 4,5,6,7-tetrahydro-2H-indazolyl.
It is to be understood that if an aryl, heteroaryl, cycloalkyl, or heterocyclyl moiety may be bonded or otherwise attached to a designated moiety through differing ring atoms (i.e., shown or described without denotation of a specific point of attachment), then all possible points are intended, whether through a carbon atom or, for example, a trivalent nitrogen atom. For example, the term “pyridinyl” means 2-, 3- or 4-pyridinyl, the term “thienyl” means 2- or 3-thienyl, and so forth.
As used herein, the phrase “protecting group” refers to a functional group introduced into a molecule by chemical modification of an oxygen atom, a nitrogen atom, or a sulfur atom to obtain chemoselectivity in a subsequent chemical reaction. Examples of hydroxyl protecting groups include, but are not limited to methoxymethyl (MOM), tetrahydropyranyl (THP), allyl, benzyl (Bn), tert-butyldimethylsilyl (TBDMS), pivaloyl (Piv), and benzoyl (Bz). Examples of nitrogen protecting groups include, but are not limited to, allyloxycarbonyl (Alloc), carbobenzyloxy (Cbz), tert-butyloxycarbonyl (Boc), 9-fluorenylmethyloxycarbonyl (Fmoc), acetyl (Ac), benzoyl (Bz), tosyl (Ts), and benzyl (Bn). Examples of sulfur protecting groups include, but are not limited to methoxymethyl (MOM), allyl, trityl (Trt), trichloroacetyl, pivaloyl (Piv), and benzoyl (Bz).
As used herein, the term “optionally substituted” means that the referenced group may be substituted or unsubstituted. As used herein, the term “substituted” means that an atom or group of atoms has replaced hydrogen as the substituent attached to another group.
Provided herein are covalent protein dimers that inhibit the activity of the MYC/MAX complex, which are useful in the treatment of MYC-related disorders, including cancer and other proliferation diseases.
In an aspect, provided herein is a covalent protein dimer, or a pharmaceutically acceptable salt thereof, comprising:
In some embodiments, the first polypeptide comprises a degree of identity of at least 90% with respect to SEQ ID NO: 1, 2, or 3. In some embodiments, the first polypeptide comprises a degree of identity of at least 95% with respect to SEQ ID NO: 1, 2, or 3. In some embodiments, the first polypeptide comprises a sequence represented by SEQ ID NO: 1, 2, or 3.
In some embodiments, the second polypeptide comprises a degree of identity of at least 90% with respect to SEQ ID NO: 1, 2, or 3. In some embodiments, the second polypeptide comprises a degree of identity of at least 95% with respect to SEQ ID NO: 1, 2, or 3. In some embodiments, the second polypeptide comprises a sequence represented by SEQ ID NO: 1, 2, or 3.
In some embodiments, the first polypeptide is at least 85% identical to SEQ ID NO: 2, and the second polypeptide is at least 85% identical to SEQ ID NO: 2; the first polypeptide is at least 85% identical to SEQ ID NO: 3, and the second polypeptide is at least 85% identical to SEQ ID NO: 3; the first polypeptide is at least 85% identical to SEQ ID NO: 1, and the second polypeptide is at least 85% identical to SEQ ID NO: 2; or the first polypeptide is at least 85% identical to SEQ ID NO: 3, and the second polypeptide is at least 85% identical to SEQ ID NO: 2.
In some embodiments, the first polypeptide is at least 85% identical to SEQ ID NO: 2, and the second polypeptide is at least 85% identical to SEQ ID NO: 2. In some embodiments, the first polypeptide is at least 90% identical to SEQ ID NO: 2, and the second polypeptide is at least 90% identical to SEQ ID NO: 2. In some embodiments, the first polypeptide is at least 95% identical to SEQ ID NO: 2, and the second polypeptide is at least 95% identical to SEQ ID NO: 2. In some embodiments, the first polypeptide comprises a sequence represented by SEQ ID NO: 2, and the second polypeptide comprises a sequence represented by SEQ ID NO: 2.
In some embodiments, the first polypeptide is at least 85% identical to SEQ ID NO: 3, and the second polypeptide is at least 85% identical to SEQ ID NO: 3. In some embodiments, the first polypeptide is at least 90% identical to SEQ ID NO: 3, and the second polypeptide is at least 90% identical to SEQ ID NO: 3. In some embodiments, the first polypeptide is at least 95% identical to SEQ ID NO: 3, and the second polypeptide is at least 95% identical to SEQ ID NO: 3. In some embodiments, the first polypeptide comprises a sequence represented by SEQ ID NO: 3, and the second polypeptide comprises a sequence represented by SEQ ID NO: 3.
In some embodiments, the first polypeptide is at least 85% identical to SEQ ID NO: 1, and the second polypeptide is at least 85% identical to SEQ ID NO: 2. In some embodiments, the first polypeptide is at least 90% identical to SEQ ID NO: 1, and the second polypeptide is at least 90% identical to SEQ ID NO: 2. In some embodiments, the first polypeptide is at least 95% identical to SEQ ID NO: 1, and the second polypeptide is at least 95% identical to SEQ ID NO: 2. In some embodiments, the first polypeptide comprises a sequence represented by SEQ ID NO: 1, and the second polypeptide comprises a sequence represented by SEQ ID NO: 2.
In some embodiments, the first polypeptide is at least 85% identical to SEQ ID NO: 3, and the second polypeptide is at least 85% identical to SEQ ID NO: 2. In some embodiments, the first polypeptide is at least 90% identical to SEQ ID NO: 3, and the second polypeptide is at least 90% identical to SEQ ID NO: 2. In some embodiments, the first polypeptide is at least 95% identical to SEQ ID NO: 3, and the second polypeptide is at least 95% identical to SEQ ID NO: 2. In some embodiments, the first polypeptide comprises a sequence represented by SEQ ID NO: 3, and the second polypeptide comprises a sequence represented by SEQ ID NO: 2.
In general, the linker is a chemical moiety comprising a covalent bond or a chain of atoms that covalently attaches the C-terminus of the first polypeptide to the C-terminus of the second polypeptide. Exemplary linkers may comprise at least one optionally substituted; saturated or unsaturated; linear, branched or cyclic alkyl group or an optionally substituted aryl group. The linker may also be a polypeptide (e.g., from about 1 to about 50 amino acids or more, or from about 1 to about 5 amino acids). In some embodiments, the linker is biologically stable and is not readily cleavable under physiological environments or conditions.
In another aspect, provided herein is a covalent protein dimer, or a pharmaceutically acceptable salt thereof, having a structure according to Formula (I):
In some embodiments, the covalent protein dimer of Formula (I) has a structure according to Formula (Ia):
In some embodiments, the covalent protein dimer of Formula (I) has a structure according to Formula (Ib):
In some embodiments, Y1 comprises a C-terminus and an N-terminus, wherein the C-terminus forms a bond with Z1 or —NH—.
In some embodiments, Y2 comprises a C-terminus and an N-terminus, wherein the C-terminus forms a bond with Z2 or —NH—.
In some embodiments, if one of Y1 or Y2 is at least 85% identical to SEQ ID NO: 1, then the other is at least 85% identical to SEQ ID NO: 2.
In some embodiments, Y1 is at least 90% identical to SEQ ID NO: 1, 2, or 3. In some embodiments, Y1 is at least 95% identical to SEQ ID NO: 1, 2, or 3. In some embodiments, Y1 comprises a sequence represented by SEQ ID NO: 1, 2, or 3.
In some embodiments, Y2 is at least 90% identical to SEQ ID NO: 1, 2, or 3. In some embodiments, Y2 is at least 95% identical to SEQ ID NO: 1, 2, or 3. In some embodiments, Y2 comprises a sequence represented by SEQ ID NO: 1, 2, or 3.
In some embodiments, Y1 is at least 85% identical to SEQ ID NO: 2, and Y2 is at least 85% identical to SEQ ID NO: 2;Y1 is at least 85% identical to SEQ ID NO: 3, and Y2 is at least 85% identical to SEQ ID NO: 3; Y1 is at least 85% identical to SEQ ID NO: 1, and Y2 is at least 85% identical to SEQ ID NO: 2; or Y1 is at least 85% identical to SEQ ID NO: 3, and Y2 is at least 85% identical to SEQ ID NO: 2.
In some embodiments, Y1 is at least 85% identical to SEQ ID NO: 2, and Y2 is at least 85% identical to SEQ ID NO: 2. In some embodiments, Y1 is at least 90% identical to SEQ ID NO: 2,and Y2 is at least 90% identical to SEQ ID NO: 2. In some embodiments, Y1 is at least 95% identical to SEQ ID NO: 2, and Y2 is at least 95% identical to SEQ ID NO: 2. In some embodiments, Y1 comprises a sequence represented by SEQ ID NO: 2, and Y2 comprises a sequence represented by SEQ ID NO: 2.
In some embodiments, Y1 is at least 85% identical to SEQ ID NO: 3, and Y2 is at least 85% identical to SEQ ID NO: 3. In some embodiments, Y1 is at least 90% identical to SEQ ID NO: 3, and Y2 is at least 90% identical to SEQ ID NO: 3. In some embodiments, Y1 is at least 95% identical to SEQ ID NO: 3, and Y2 is at least 95% identical to SEQ ID NO: 3. In some embodiments, Y1 comprises a sequence represented by SEQ ID NO: 3, and Y2 comprises a sequence represented by SEQ ID NO: 3.
In some embodiments, Y1 is at least 85% identical to SEQ ID NO: 1, and Y2 is at least 85% identical to SEQ ID NO: 2. In some embodiments, Y1 is at least 90% identical to SEQ ID NO: 1, and Y2 is at least 90% identical to SEQ ID NO: 2. In some embodiments, Y1 is at least 95% identical to SEQ ID NO: 1,and Y2 is at least 95% identical to SEQ ID NO: 2. In some embodiments, Y1 comprises a sequence represented by SEQ ID NO: 1, and Y2 comprises a sequence represented by SEQ ID NO: 2.
In some embodiments, Y1 is at least 85% identical to SEQ ID NO: 3, and Y2 is at least 85% identical to SEQ ID NO: 2. In some embodiments, Y1 is at least 90% identical to SEQ ID NO: 3, and Y2 is at least 90% identical to SEQ ID NO: 2. In some embodiments, Y1 is at least 95% identical to SEQ ID NO: 3, and Y2 is at least 95% identical to SEQ ID NO: 2. In some embodiments, Y1 comprises a sequence represented by SEQ ID NO: 3, and Y2 comprises a sequence represented by SEQ ID NO: 2.
In some embodiments, Z1 is —NH—. In some embodiments, Z2 is —NH—.
In some embodiments, R1 is absent or C1-10 alkyl. In some embodiments, R2 is absent or C1-10 alkyl.
In some embodiments, W is C1-10 alkyl or C1-10 heteroalkyl. In some embodiments, W is C1-5 alkyl or C1-5 heteroalkyl.
In some embodiments, L is absent.
In some embodiments, L is a linker. Exemplary linkers may comprise at least one optionally substituted; saturated or unsaturated; linear, branched or cyclic alkyl group or an optionally substituted aryl group. In some embodiments, the linker is a polypeptide. In some embodiments, the linker comprises one to fifty amino acids. In some embodiments, the linker comprises one to twenty-five amino acids. In some embodiments, the linker comprises one to ten amino acids. In some embodiments, the linker comprises one to five amino acids. In some embodiments, L is β-alanine.
In some embodiments, R is H.
In some embodiments, R is a nitrogen protecting group that is not 9-fluorenylmethyloxycarbonyl (Fmoc). In some embodiments, R is a nitrogen protecting group selected from the group consisting of allyloxycarbonyl (Alloc), carbobenzyloxy (Cbz), tert-butyloxycarbonyl (Boc), acetyl (Ac), benzoyl (Bz), tosyl (Ts), and benzyl (Bn). In some embodiments, R is Alloc or Boc.
In some embodiments, R is a fluorescent dye. Fluorescent dyes suitable for the covalent protein dimers include any fluorescent dye known in the art that may be covalently linked to dimer by way of the nitrogen atom adjacent variable R. Non-limiting examples of fluorescent dyes include Alexa Fluor fluorescent dyes, DyLight Fluor fluorescent dyes, rhodamine dyes, blue fluorescent protein (BFP), cyan fluorescent protein (CFP), green fluorescent protein (GFP), enhanced green fluorescent protein (eGFP), Cascade Blue™, Marina Blue™, Pacific Orange™, Oregon Green™, Cascade Yellow™, BODIPY, coumarin, methoxycoumarin, aminomethylcoumarin (AMCA), dansyl, 5-TAMRA, fluorescein, mBanana, mOrange, mHoneydew, mTangerine, mCherry, and mPlum. In some embodiments, the fluorescent dye is 5-TAMRA.
In some embodiments, R is a nuclear targeting moiety. In some embodiments, R is Mach3 having the sequence:
wherein Xaa is 6-aminohexanoic acid.
In some embodiments, n is 0. In some embodiments, n is 1.
In another aspect, provided herein is a covalent protein dimer, or a pharmaceutically acceptable salt thereof, having a structure according to Formula (II):
In some embodiments, the covalent protein dimer of Formula (II) has a structure according to Formula (IIa):
In some embodiments, the covalent protein dimer of Formula (II) has a structure according to Formula (IIb):
In some embodiments, Y1 comprises a C-terminus and an N-terminus, wherein the C-terminus forms a bond with Z2 or —NH—.
In some embodiments, Y2 comprises a C-terminus and an N-terminus, wherein the C-terminus forms a bond with Z2 or —NH—.
In some embodiments, Y1 is at least 90% identical to SEQ ID NO: 1, 2, or 3. In some embodiments, Y1 is at least 95% identical to SEQ ID NO: 1, 2, or 3. In some embodiments, Y1 comprises a sequence represented by SEQ ID NO: 1, 2, or 3.
In some embodiments, Y2 is at least 90% identical to SEQ ID NO: 1, 2, or 3. In some embodiments, Y2 is at least 95% identical to SEQ ID NO: 1, 2, or 3. In some embodiments, Y2 comprises a sequence represented by SEQ ID NO: 1, 2, or 3.
In some embodiments, Y1 is at least 85% identical to SEQ ID NO: 2, and Y2 is at least 85% identical to SEQ ID NO: 2; Y1 is at least 85% identical to SEQ ID NO: 3, and Y2 is at least 85% identical to SEQ ID NO: 3; Y1 is at least 85% identical to SEQ ID NO: 1, and Y2 is at least 85% identical to SEQ ID NO: 1; Y1 is at least 85% identical to SEQ ID NO: 1, and Y2 is at least 85% identical to SEQ ID NO: 2; Y1 is at least 85% identical to SEQ ID NO: 3, and Y2 is at least 85% identical to SEQ ID NO: 2; or Y1 is at least 85% identical to SEQ ID NO: 3, and Y2 is at least 85% identical to SEQ ID NO: 1;.
In some embodiments, Y1 is at least 85% identical to SEQ ID NO: 2, and Y2 is at least 85% identical to SEQ ID NO: 2. In some embodiments, Y1 is at least 90% identical to SEQ ID NO: 2, and Y2 is at least 90% identical to SEQ ID NO: 2. In some embodiments, Y1 is at least 95% identical to SEQ ID NO: 2, and Y2 is at least 95% identical to SEQ ID NO: 2. In some embodiments, Y1 comprises a sequence represented by SEQ ID NO: 2, and Y2 comprises a sequence represented by SEQ ID NO: 2.
In some embodiments, Y1 is at least 85% identical to SEQ ID NO: 3, and Y2 is at least 85% identical to SEQ ID NO: 3. In some embodiments, Y1 is at least 90% identical to SEQ ID NO: 3, and Y2 is at least 90% identical to SEQ ID NO: 3. In some embodiments, Y1 is at least 95% identical to SEQ ID NO: 3, and Y2 is at least 95% identical to SEQ ID NO: 3. In some embodiments, Y1 comprises a sequence represented by SEQ ID NO: 3, and Y2 comprises a sequence represented by SEQ ID NO: 3.
In some embodiments, Y1 is at least 85% identical to SEQ ID NO: 1, and Y2 is at least 85% identical to SEQ ID NO: 1. In some embodiments, Y1 is at least 90% identical to SEQ ID NO: 1, and Y2 is at least 90% identical to SEQ ID NO: 1. In some embodiments, Y1 is at least 95% identical to SEQ ID NO: 1, and Y2 is at least 95% identical to SEQ ID NO: 1. In some embodiments, Y1 comprises a sequence represented by SEQ ID NO: 1, and Y2 comprises a sequence represented by SEQ ID NO: 1.
In some embodiments, Y1 is at least 85% identical to SEQ ID NO: 1, and Y2 is at least 85% identical to SEQ ID NO: 2. In some embodiments, Y1 is at least 90% identical to SEQ ID NO: 1, and Y2 is at least 90% identical to SEQ ID NO: 2. In some embodiments, Y1 is at least 95% identical to SEQ ID NO: 1, and Y2 is at least 95% identical to SEQ ID NO: 2. In some embodiments, Y1 comprises a sequence represented by SEQ ID NO: 1, and Y2 comprises a sequence represented by SEQ ID NO: 2.
In some embodiments, Y1 is at least 85% identical to SEQ ID NO: 3, and Y2 is at least 85% identical to SEQ ID NO: 2. In some embodiments, Y1 is at least 90% identical to SEQ ID NO: 3, and Y2 is at least 90% identical to SEQ ID NO: 2. In some embodiments, Y1 is at least 95% identical to SEQ ID NO: 3, and Y2 is at least 95% identical to SEQ ID NO: 2. In some embodiments, Y1 comprises a sequence represented by SEQ ID NO: 3, and Y2 comprises a sequence represented by SEQ ID NO: 2.
In some embodiments, Y1 is at least 85% identical to SEQ ID NO: 3, and Y2 is at least 85% identical to SEQ ID NO: 1. In some embodiments, Y1 is at least 90% identical to SEQ ID NO: 3, and Y2 is at least 90% identical to SEQ ID NO: 1. In some embodiments, Y1 is at least 95% identical to SEQ ID NO: 3, and Y2 is at least 95% identical to SEQ ID NO: 1. In some embodiments, Y1 comprises a sequence represented by SEQ ID NO: 3, and Y2 comprises a sequence represented by SEQ ID NO: 1.
In some embodiments, Z1 is —S—. In some embodiments, Z2 is —NH—.
In some embodiments, R1 is C1-10 alkyl. In some embodiments, R1 is C1-5 alkyl or C1-5 heteroalkyl.
In some embodiments, A is C6-10 aryl. In some embodiments, A is 5- to 10-membered heteroaryl. In some embodiments, A is phenyl or 5- to 6-membered heteroaryl. In some embodiments, A is phenyl.
In some embodiments, L is absent.
In some embodiments, L is a linker. Exemplary linkers may comprise at least one optionally substituted; saturated or unsaturated; linear, branched or cyclic alkyl group or an optionally substituted aryl group. In some embodiments, the linker is a polypeptide. In some embodiments, the linker comprises one to fifty amino acids. In some embodiments, the linker comprises one to twenty-five amino acids. In some embodiments, the linker comprises one to ten amino acids. In some embodiments, the linker comprises one to five amino acids. In some embodiments, L is β-alanine.
In some embodiments, R is a nitrogen protecting group that is not 9-fluorenylmethyloxycarbonyl (Fmoc). In some embodiments, R is a nitrogen protecting group selected from the group consisting of allyloxycarbonyl (Alloc), carbobenzyloxy (Cbz), tert-butyloxycarbonyl (Boc), acetyl (Ac), benzoyl (Bz), tosyl (Ts), and benzyl (Bn). In some embodiments, R is Alloc or Boc.
In some embodiments, R is a fluorescent dye. Fluorescent dyes suitable for the covalent protein dimers include any fluorescent dye known in the art that may be covalently linked to dimer by way of the nitrogen atom adjacent variable R. Non-limiting examples of fluorescent dyes include Alexa Fluor fluorescent dyes, DyLight Fluor fluorescent dyes, rhodamine dyes, blue fluorescent protein (BFP), cyan fluorescent protein (CFP), green fluorescent protein (GFP), enhanced green fluorescent protein (eGFP), Cascade Blue™, Marina Blue™, Pacific Orange™, Oregon Green™, Cascade Yellow™, BODIPY, coumarin, methoxycoumarin, aminomethylcoumarin (AMCA), dansyl, 5-TAMRA, fluorescein, mBanana, mOrange, mHoneydew, mTangerine, mCherry, and mPlum. In some embodiments, the fluorescent dye is 5-TAMRA.
In some embodiments, R is a nuclear targeting moiety. In some embodiments, R is Mach3 having the sequence:
wherein Xaa is 6-aminohexanoic acid.
In some embodiments, n is 0. In some embodiments, n is 1.
The covalent protein dimers disclosed herein may exist as tautomers and optical isomers (e.g., enantiomers, diastereomers, diastereomeric mixtures, racemic mixtures, and the like).
In an aspect, provided herein is a pharmaceutical composition comprising a covalent protein dimer disclosed herein and a pharmaceutically acceptable carrier.
In an embodiment, the pharmaceutical compositions described herein include a therapeutically or prophylactically effective amount of a compound described herein. The pharmaceutical composition may be useful for treating a proliferative disease in a subject in need thereof, preventing a proliferative disease in a subject in need thereof, or inhibiting the activity of MYC in a subject, biological sample, tissue, or cell. In some embodiments, the proliferative disease is cancer.
Also provided herein are methods of making the covalent protein dimers disclosed herein. Accordingly, in an aspect, the disclosure provides a method of making a covalent protein dimer, or a pharmaceutically acceptable salt thereof, having a structure according to Formula (I):
and
In some embodiments, the covalent protein dimer of Formula (I) has a structure according to Formula (Ia):
and
In some embodiments, the covalent protein dimer of Formula (I) has a structure according to Formula (Ib):
and
In some embodiments, Y1 and Y2 are not identical.
In some embodiments, PG1 is selected from the group consisting of allyloxycarbonyl (Alloc), carbobenzyloxy (Cbz), tert-butyloxycarbonyl (Boc), acetyl (Ac), benzoyl (Bz), tosyl (Ts), and benzyl (Bn). In some embodiments, PG1 is Boc.
In some embodiments, Z1 and Z2 are —NH—, and PG2 is a nitrogen protecting group. In some embodiments, Z1 is —NH—, and PG2 is selected from the group consisting of allyloxycarbonyl (Alloc), carbobenzyloxy (Cbz), tert-butyloxycarbonyl (Boc), acetyl (Ac), benzoyl (Bz), tosyl (Ts), and benzyl (Bn). In some embodiments, Z1 is —NH—, and PG2 is Alloc.
In some embodiments, prior to step (d), the method comprises removing PG1 to provide a deprotected nitrogen atom therein, and covalently attaching biotin, a fluorescent dye, a nuclear-targeting moiety, or a cell-penetrating moiety to the deprotected nitrogen atom.
In some embodiments, each of the one or more amino acids of steps (a) and (c) comprises an Fmoc-protected backbone amino group, wherein the corresponding Fmoc group is deprotected after each amino acid is attached to the resin-bound, side-chain-protected peptide.
In some embodiments, each one of steps (a) and (c) is performed in the presence of a coupling agent. Coupling agents suitable for the methods disclosed herein include those known in the art to facilitate peptide bond formation. Exemplary non-limiting coupling agents include (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP), hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU), hexafluorophosphate benzotriazole tetramethyl uronium (HBTU), 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU), and hydroxybenzotriazole (HOBt).
In some embodiments, each one of steps (a) and (c) comprises the addition of N,N-diisopropylethylamine (DIEA).
In another aspect, the disclosure provides a method of making a covalent protein dimer, or a pharmaceutically acceptable salt thereof, having a structure according to Formula (I):
In some embodiments, the covalent protein dimer of Formula (I) has a structure according to Formula (Ia):
In some embodiments, the covalent protein dimer of Formula (I) has a structure according to Formula (Ib):
In some embodiments, PG1 is selected from the group consisting of allyloxycarbonyl (Alloc), carbobenzyloxy (Cbz), tert-butyloxycarbonyl (Boc), acetyl (Ac), benzoyl (Bz), tosyl (Ts), and benzyl (Bn). In some embodiments, PG1 is Alloc.
In some embodiments, Z1 and Z2 are —NH—.
In some embodiments, prior to step (b), the method comprises removing PG1 to provide a deprotected nitrogen atom therein, and covalently attaching biotin, a fluorescent dye, a nuclear-targeting moiety, or a cell-penetrating moiety to the deprotected nitrogen atom.
In some embodiments, each of the one or more amino acids of step (a) comprise an Fmoc-protected backbone amino group, and wherein the corresponding Fmoc group is deprotected after each amino acid is attached to the resin-bound, side-chain-protected peptide.
In some embodiments, step (a) is performed in the presence of a coupling agent. Exemplary non-limiting coupling agents include (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP), hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU), hexafluorophosphate benzotriazole tetramethyl uronium (HBTU), 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU), and hydroxybenzotriazole (HOBt).
In some embodiments, step (a) comprises the addition of N,N-Diisopropylethylamine (DIEA).
In another aspect, the disclosure provides a method of making a covalent protein dimer, or a pharmaceutically acceptable salt thereof, having a structure according to Formula (II):
with a compound of Formula (IX):
to provide a polypeptide having a structure according to Formula (X):
In some embodiments, the covalent protein dimer of Formula (II) has a structure according to Formula (IIa):
with a compound of Formula (IX):
to provide a polypeptide having a structure according to Formula (Xa):
In some embodiments, the covalent protein dimer of Formula (II) has a structure according to Formula (IIb):
with a compound of Formula (IX):
to provide a polypeptide having a structure according to Formula (Xb):
In some embodiments, Y1 and Y2 are not identical.
In some embodiments, Z1 is —S—. In some embodiments, Z2 is —NH—.
In some embodiments, the compound of Formula (IX), (IXa), or (IXb) is provided in molar excess with respect to the polypeptide of Formula (VIII), (VIIIa), or (VIIIb). In some embodiments, the compound of Formula (IX), (IXa), or (IXb) and the polypeptide of Formula (VIII), (VIIIa), or (VIIIb) are provided in a molar ratio from about 10:1 to about 2:1. In some embodiments the compound of Formula (IX), (IXa), or (IXb) and the polypeptide of Formula (VIII), (VIIIa), or (VIIIb) are provided in a molar ratio of about 5:1.
In some embodiments, X and X′ are I.
wherein:
In some embodiments, Lig is
In another aspect, the disclosure provides a method of making a covalent protein dimer having a structure according to Formula (II):
with a compound of Formula (IX):
to provide the covalent protein dimer,
In some embodiments, the covalent protein dimer of Formula (II) has a structure according to Formula (IIa):
with a compound of Formula (IX):
to provide the covalent protein dimer;
In some embodiments, the covalent protein dimer of Formula (II) has a structure according to Formula (IIb):
with a compound of Formula (IX):
to provide the covalent protein dimer,
wherein:
In some embodiments, Lig is
In an aspect, provided herein is a method of treating a disease or disorder characterized by MYC dysregulation in a subject in need thereof, the method comprising administering to the subject a covalent protein dimer of the present disclosure. In some embodiments, the disease or disorder characterized by MYC dysregulation is an immune disorder, such as myasthenia gravis, psoriasis, pemphigus vulgaris, and atherosclerosis. In some embodiments, the disease or disorder is cancer. In certain embodiments, the cancer is selected from the group consisting of pancreatic cancer, lung cancer, prostate cancer, breast cancer, ovarian cancer, kidney cancer, liver cancer, brain cancer, neuroblastoma, colorectal cancer, and hematological malignancies.
Also described are methods for contacting a cell or a biological sample with an effective amount of a covalent protein dimer of the disclosure.
In yet another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a covalent protein dimer of the present disclosure.
The term “cancer” refers to any cancer caused by the proliferation of malignant neoplastic cells, such as tumors, neoplasms, carcinomas, sarcomas, leukemias, lymphomas and the like. For example, cancers include, but are not limited to, mesothelioma, leukemias and lymphomas such as cutaneous T-cell lymphomas (CTCL), noncutaneous peripheral T-cell lymphomas, lymphomas associated with human T-cell lymphotrophic virus (HTLV) such as adult T-cell leukemia/lymphoma (ATLL), B-cell lymphoma, acute nonlymphocytic leukemias, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, lymphomas, and multiple myeloma, non-Hodgkin lymphoma, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), Hodgkin's lymphoma, Burkitt lymphoma, adult T-cell leukemia lymphoma, acute-myeloid leukemia (AML), chronic myeloid leukemia (CML), or hepatocellular carcinoma. Further examples include myelodysplastic syndrome, childhood solid tumors such as brain tumors, neuroblastoma, retinoblastoma, Wilms' tumor, bone tumors, and soft-tissue sarcomas, common solid tumors of adults such as head and neck cancers (e.g., oral, laryngeal, nasopharyngeal and esophageal), genitourinary cancers (e.g., prostate, bladder, renal, uterine, ovarian, testicular), lung cancer (e.g., small-cell and non-small cell), breast cancer, pancreatic cancer, melanoma and other skin cancers, stomach cancer, brain tumors, tumors related to Gorlin syndrome (e.g., medulloblastoma, meningioma, etc.), and liver cancer. Additional exemplary forms of cancer which may be treated by the subject compounds include, but are not limited to, cancer of skeletal or smooth muscle, stomach cancer, cancer of the small intestine, rectum carcinoma, cancer of the salivary gland, endometrial cancer, adrenal cancer, anal cancer, rectal cancer, parathyroid cancer, and pituitary cancer.
Additional cancers that the covalent protein dimers described herein may be useful in preventing, treating and studying are, for example, colon carcinoma, familial adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer, or melanoma. Further, cancers include, but are not limited to, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, thyroid cancer (medullary and papillary thyroid carcinoma), renal carcinoma, kidney parenchyma carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, testis carcinoma, urinary carcinoma, melanoma, brain tumors such as glioblastoma, astrocytoma, meningioma, medulloblastoma and peripheral neuroectodermal tumors, gall bladder carcinoma, bronchial carcinoma, multiple myeloma, basalioma, teratoma, retinoblastoma, choroidea melanoma, seminoma, rhabdomyosarcoma, craniopharyngeoma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma, and plasmocytoma.
In some embodiments, the cancer is lung cancer, colon cancer, breast cancer, prostate cancer, liver cancer, pancreas cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemias, lymphomas, myelomas, or solid tumors. In further embodiments, the disease is lung cancer, breast cancer, ovarian cancer, glioma, squamous cell carcinoma, or prostate cancer. In some embodiments, the cancer is breast cancer, colorectal cancer, pancreatic cancer, gastric cancer, or uterine cancer. In some embodiments, the cancer is a hematological malignancy. In some embodiments, the cancer is acute myeloid leukemia, chronic myelogenous leukemia, Hodgkin's lymphoma, or diffuse large B-cell lymphoma. In some embodiments, the cancer is lung cancer. In some embodiments, the cancer is a non-small cell lung cancer.
In some embodiments, the covalent protein dimes of this disclosure are useful for treating cancer, such as colorectal, thyroid, breast, and lung cancer; and myeloproliferative disorders, such as polycythemia vera, thrombocythemia, myeloid metaplasia with myelofibrosis, chronic myelogenous leukemia, chronic myelomonocytic leukemia, hypereosinophilic syndrome, juvenile myelomonocytic leukemia, and systemic mast cell disease. In some embodiments, the covalent protein dimers of this disclosure are useful for treating hematopoietic disorders acute-myelogenous leukemia (AML), chronic-myelogenous leukemia (CML), acute-promyelocytic leukemia, and acute lymphocytic leukemia (ALL).
In one aspect, the present disclosure provides for the use of one or more covalent protein dimers of the disclosure in the manufacture of a medicament for the treatment of cancer, including without limitation the various types of cancer disclosed herein.
The covalent protein dimers described herein will generally be administered to a subject as a pharmaceutical composition. The terms “patient” and “subject”, as used herein, include humans and non-human animals. The covalent protein dimers described herein may be employed therapeutically, under the guidance of a physician.
The compositions comprising the covalent protein dimers of the instant disclosure may be conveniently formulated for administration with any pharmaceutically acceptable carrier(s). For example, the covalent protein dimers may be formulated with an acceptable medium such as water, buffered saline, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), dimethyl sulfoxide (DMSO), oils, detergents, suspending agents or suitable mixtures thereof. The concentration of the covalent protein dimers in the chosen medium may be varied and the medium may be chosen based on the desired route of administration of the pharmaceutical composition. Except insofar as any conventional media or agent is incompatible with the covalent protein dimers to be administered, its use in the pharmaceutical composition is contemplated.
The dose and dosage regimen of the covalent protein dimers disclosed herein that are suitable for administration to a particular subject may be determined by a physician considering the subject's age, sex, weight, general medical condition, and the specific condition for which the covalent protein dimer(s) is being administered and the severity thereof. The physician may also take into account the route of administration, the pharmaceutical carrier, and the covalent protein dimers' biological activity.
Selection of a suitable pharmaceutical composition will also depend upon the mode of administration chosen. For example, the covalent protein dimers of the invention may be administered by direct injection to a desired site (e.g., tumor). In this instance, a pharmaceutical composition comprising the covalent protein dimers is dispersed in a medium that is compatible with the site of injection. Covalent protein dimers of the instant disclosure may be administered by any method. For example, the covalent protein dimers of the instant disclosure can be administered, without limitation parenterally, subcutaneously, orally, topically, pulmonarily, rectally, vaginally, intravenously, intraperitoneally, intrathecally, intracerbrally, epidurally, intramuscularly, intradermally, or intracarotidly.
Pharmaceutical compositions containing a covalent protein dimer of the present disclosure as the active ingredient in intimate admixture with a pharmaceutically acceptable carrier can be prepared according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral, direct injection, intracranial, and intravitreal.
A pharmaceutical composition of the disclosure may be formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to a physically discrete unit of the pharmaceutical preparation appropriate for the patient undergoing treatment. Each dosage should contain a quantity of active ingredient calculated to produce the desired effect in association with the selected pharmaceutical carrier. Procedures for determining the appropriate dosage unit are well known to those skilled in the art.
Dosage units may be proportionately increased or decreased based on the weight of the subject. Appropriate concentrations for alleviation of a particular pathological condition may be determined by dosage concentration curve calculations, as known in the art.
In accordance with the present disclosure, the appropriate dosage unit for the administration of covalent protein dimers may be determined by evaluating the toxicity of the molecules or cells in animal models. Various concentrations of covalent protein dimers in pharmaceutical preparations may be administered to mice, and the minimal and maximal dosages may be determined based on the beneficial results and side effects observed as a result of the treatment. Appropriate dosage units may also be determined by assessing the efficacy of the covalent protein dimers in combination with other standard drugs. The dosage units of covalent protein dimers may be determined individually or in combination with each treatment according to the effect detected.
The pharmaceutical compositions comprising the covalent protein dimers may be administered at appropriate intervals, for example, at least twice a day or more until the pathological symptoms are reduced or alleviated, after which the dosage may be reduced to a maintenance level. The appropriate interval in a particular case would normally depend on the condition of the subject.
The disclosure is further illustrated by the following examples, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure and/or scope of the appended claims.
Preparation of ChemMatrix® Rink amide resin (loading 0.18 mmol/g, typical scale: 100 mg, 0.02 mmol) was loaded into a fritted syringe (6 mL), swollen in DMF (4 mL) for 5 minutes and then drained. Each Na-Fmoc protected amino acid (0.2 mmol, 10 equiv.) was dissolved in DMF containing 0.39 M HATU (0.5 mL). Immediately before the coupling, DIEA (100 μL, 30 equiv.) was added to the mixture to activate the amino acid. After 15 seconds preactivation, the mixture was added to the resin and reacted for 10 min, with occasional stirring. After completion of the coupling step, the syringe was drained, and the resin was washed with DMF (3×5 mL). Fmoc deprotection was performed by addition of piperidine (20% in DMF, 3 mL) to the resin (1×1 min+1×5 min), followed by draining and washing the resin with DMF (5×5 mL). For peptidyl resin 1 the coupling cycles were performed sequentially with Fmoc-Lys (Alloc)—OH, Fmoc-βAla-OH, and Fmoc-Lys (Fmoc)—OH; for peptidyl resin 2 the coupling cycles were performed sequentially with Fmoc-Lys (Boc)—OH, Fmoc-βAla-OH and Fmoc-Lys (Alloc)—OH.
Covalent MAX-MAX and Omomyc-Omomyc homodimers were prepared via parallel single-shot fast-flow solid-phase synthesis from peptidyl resin 1. Each step involved the parallel coupling and subsequent deprotection of two amino acids simultaneously. The synthesis time for each homodimer was about 3.5 hours (MAX-MAX (3), 164 residues; Omomyc-Omomyc (4), 184 residues). After cleavage and side-chain deprotection, LC-MS analysis indicated the desired products as the major component of both crude reaction mixtures. Upon preparative HPLC purification, pure MAX-MAX (3) and Omomyc-Omomyc (4) were obtained in 6% and 8% yield, respectively.
Covalent MYC-MAX and Omomyc-MAX heterodimers were prepared by consecutive single-shot fast flow solid phase synthesis. With the fast flow synthesizer, MAX was assembled from the α-amine of the lysine linker of peptidyl resin 2. For the last amino acid, Boc-glycine was added, and the Alloc protection was removed from the NE of the lysine linker. On this amine, MYC or Omomyc were assembled to provide 5 and 6, respectively. The synthesis time for each heterodimer amounted to about 8 hours (MYC-MAX (5), 167 residues; Omomyc-MAX (6), 175 residues). Both heterodimers were observed as the main component of the crude product mixture obtained from cleavage and side-chain deprotection. Upon preparative HPLC purification, pure MYC-MAX (5) and Omomyc-MAX (6) dimers were obtained in 4% and 5% yield, respectively.
All peptides were synthesized on two automated-flow systems depicted in
For heterodimers 5 and 6, prior to site-selective modification via the Alloc protected lysine, the protein N-termini was blocked with Boc-Gly-OH: Peptidyl resin (˜10 μmol theoretical loading) was loaded into a fritted syringe (6 mL), swollen in DMF (4 mL) for 5 minutes and then drained. Boc-Gly-OH (18 mg, 100 μmol) and HATU (54 mg, 90 μmol) were dissolved in DMF (250 μL), activated with DIEA (38 mg, 52 μL, 300 μmol), added to the peptidyl resin and incubated for 15 minutes. After this time, the resin was drained, washed with DMF (3×5 mL) and used for the next step.
The peptidyl resin (˜10 μmol theoretical loading) was washed with dichloromethane (3×5 mL) and then treated with Pd(PPh3)4 (11.0 mg, 10 μmol, 1 equiv) in dichloromethane/piperidine (8:2, 1 mL) for 30 minutes at room temperature under exclusion of light. The resin was then drained and washed with dichloromethane (3×5 mL).
Starting from homodimer 3 or 4, N-termini Boc-protection and Alloc deprotection of the C-terminal lysine was performed according to the protocols above. Mach3 (SEQ ID NO: 4) was installed via AFPS from the resulting free amine. For TAMRA installation, the peptidyl resin (˜10 μmol theoretical loading) was loaded into a fritted syringe (6 mL), swollen in DMF (4 mL) for 5 minutes and then drained. 5-Carboxytetramethylrhodamine (5-TAMRA, 22 mg, 50 μmol, 5 equivalents) and HATU (17 mg, 45 μmol, 4.5 equivalents) were dissolved in DMF (500 μL), activated with DIEA (19 mg, 26 μL, 150 μmol), added to the peptidyl resin and incubated for 30 minutes under exclusion of light. After this time, the resin was drained, washed with DMF (3×5 mL), and stored until cleavage.
After synthesis, the peptidyl resin was washed with dichloromethane (3×5 mL) and dried. Approximately 8 mL of cleavage solution (82.5% TFA, 5% water, 5% phenol, 5% thioanisole, 2.5% EDT) was added to the peptidyl resin inside the fritted syringe. The cleavage was kept at room temperature for 4 h, with occasional shaking. After this time, the cleavage mixture was transferred to a falcon tube (through the syringe frit, keeping the resin in the syringe), and the resin washed with an additional 2 mL of cleavage solution. Ice cold diethyl ether (45 mL) was added to the cleavage mixture and the precipitate was collected by centrifugation and triturated twice more with cold diethyl ether (45 mL). The supernatant was discarded. Residual ether was allowed to evaporate, and the peptide was dissolved in 50% acetonitrile in water with 0.1% TFA (long peptides were dissolved 70% acetonitrile in water with 0.1% TFA). The peptide solution was filtrated with a Nylon 0.22 um syringe filter and frozen and then lyophilized until dry.
Biophysical characterization confirmed the folding and DNA-binding activity of the four covalent protein dimers 3, 4, 5, and 6. The dimers were first analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). All dimer constructs had bands at the expected height of ˜20 kDa, and the monomers MYC, MAX, and Omomyc (synthesized by AFPS) were observed at ˜10 kDa. The refolding of the protein dimers did not require special procedures. The lyophilized dimers were dissolved in folding buffer (MES 10 mM, KCl 150 mM, MgCl2 1 mM, TCEP 1 mM, glycerol 10%, pH=6.5) and all four dimers displayed defined α-helical signatures, as determined by circular dichroism (CD). Next an electrophoretic mobility shift assay (EMSA) was performed to determine the dimers' DNA binding activity. At a DNA concentration of 1 μM and protein concentration of 2 μM, all dimers formed complexes with the E-Box DNA, as observed by the shift retardation on the gel. Monomeric MYC, tested as a negative control (4 μM), did not bind to E-box DNA.
Covalently linked dimers have stabilized structures in aqueous buffer compared to their non-covalent analogs. CD signals at 221 nm between 4 and 89° C. were recorded to determine melting temperatures (Tm). Using this method, the non-covalent MAX/MAX and Omomyc/Omomyc dimers were compared to the four synthetic covalent protein dimers (3, 4, 5, and 6). Protein melting temperature measurements were also performed in the presence of equimolar E-Box DNA. Overall the DNA stabilized the protein complexes' structures. The covalent linkage showed a significant stabilizing effect on the MAX dimers: The Tm of the non-covalent MAX structure was determined to be 29° C. while the Tm of the covalent dimer was 38° C. Omomyc complexes, overall, displayed higher structural stability than the other dimers tested. A significant Tm difference was not observed for non-covalent Omomyc compared to covalent Omomyc-Omomyc (4). This observation might be explained by the greater stability of the Omomyc leucine zipper. The most stable complex of all structures tested was the covalent Omomyc-Omomyc dimer (4) in the presence of DNA, with a Tm of 67° C. Finally, the proteolytic stability of dimer 4 was tested. After 1 h incubation in human serum (5% in PBS) at 37° C. 91% of intact protein dimer was found.
SDS-PAGE analysis was performed using Bolt™ 4-12% Bis-Tris Plus Gels (10-wells) at 165 V for 36 min utilizing pre-stained Invitrogen SeeBlue™ Plus2 molecular weight standard. Bolt™ LDS Sample Buffer (4×) was added to each protein sample (1 μg) for loading on the gel. The bands were visualized by Coomassie blue staining.
The E-Box DNA probe (2 μM in binding buffer) was heated to 95° C. for 5 minutes and then let cool down to room temperature over 15 minutes for double-strand annealing. Protein dimer (4 μM in binding buffer: MES 10 mM, KCl 150 mM, MgCl2 1 mM, TCEP 1 mM, glycerol 10%, pH=6.5) was added to the DNA (final concentrations: 2 μM protein and 1 μM DNA) and the mixture was incubated for 1 h at room temperature. During the incubation, a 10% polyacrylamide gel was prerun (1 h, 4° C., 100 V) in 1× TBE buffer. After that time, DNA protein mixture (20 μL) was mixed with 6× DNA Loading Dye (4 μL)) and loaded on the gel, which was run at 75 V, for 90 min at 4° C. The gel was washed with water for 20 seconds and then stained with 0.02% ethidium bromide in 1xTBE buffer for 15 min at room temperature. Bands were visualized on a Biorad Gel imager.
Lyophilized samples were dissolved in folding buffer (MES 10 mM, KCl 150 mM, MgCl2 1 mM, TCEP 1 mM, glycerol 10%, pH=6.5) at a final protein concentration of 0.1 mg/mL. The circular dichroism (CD) spectra were obtained using an AVIV 420 circular dichroism spectrometer with a 1 mm path length quartz cuvette. 300 μL sample were used for each measurement. For full wavelength scans the CD spectra were recorded from 250 to 200 nm at 4° C. with three seconds averaging times at each wavelength. Y-axis values are reported in molar ellipticity. For melting temperature determination CD spectra were recorded at 221 nm from 4 to 89° C., with +5 degree steps and equilibration times of 60 seconds at each temperature. For measurements in of DNA/protein complexes equimolar E-Box DNA was added to the proteins in folding buffer; the mixtures were heated to 95° C. for 5 minutes, let cool down to room temperature over 15 minutes and then analyzed.
Covalent dimers 7, 8, and 9 were used to assess cell penetration via microscopy and flow cytometry. To evaluate uptake, Hela cells were treated with fluorophore-labeled dimers (7, 8, and 9) and fluorescence was measured via flow cytometry. All three analogs are taken up into cells in a dose-dependent manner after a brief (15 min) incubation (
HeLa (ATCC CCL-2), A549 (ATCC CCL-185), and H441 (ATCC HTB-174) cancer cell lines were maintained in MEM, FK-12, and RPMI-1640 media each containing 10% v/v fetal bovine serum (FBS) and 1% v/v penicillin-streptomycin, respectively, at 37° C. and 5% CO2. Cells were passaged at 80% confluency using 0.25% trypsin-EDTA.
Hela cells were plated at 10,000 cells per well in a 96-well plate the night before the experiment. On the day of, cells were treated with the indicated concentrations of TAMRA-Omomyc, 7, 8, or 9 for 15 minutes in serum-containing culture medium, washed once with PBS, and treated with 0.25% trypsin-EDTA for 30 minutes to digest membrane-bound protein, at 37° C. and 5% CO2. Cells were then washed with PBS, incubated in PBS containing 1× DAPI for three minutes, and then resuspended in PBS containing 2% FBS. Cells were then immediately analyzed on a BD FACS LSR II using DAPI and PE channels.
Hela cells were plated at 10,000 cells/well in a 96-well 30 mm glass-bottom plate the night before the experiment. On the day of, cells were treated with TAMRA-Omomyc, 7, 8, or 9 (5 μM) in complete medium for 15 minutes, washed twice with fresh medium, and incubated at 37° C. and 5% CO2 for 1 h before imaging. Micrographs were obtained in the W.M. Keck microscopy facility on an RPI Spinning Disk Confocal microscope on RFP setting (561 nm 100 mW OPSL excitation laser, 605/70 nm emission) and DAPI setting (405 nm 100 mW OPSL excitation laser, 450/50 nm emission).
The covalent protein dimers inhibit the proliferation of cancer cells. MYC is known to drive cell proliferation in the majority of human cancers. The bioactivity of all compounds was tested in three cell lines with a range of MYC expression levels (see Example 3 for cell culture protocols); HeLa contains high MYC levels, A549 contains mid-level, and H441 has low MYC expression. The cells were treated for 72 hours with covalent protein dimers and the proliferation was measured with a CellTiter-Glo® (CTG) assay. Cell proliferation inhibition followed the expected trend according to MYC expression levels; the most substantial inhibition was observed in Hela cells and the weakest in H441 cells. All synthetic dimers demonstrated inhibitory activity, with 4 having the highest activity with an EC50 of 4 μM. This observation is in line with the structural stability data. Moreover, 9 further decreased the EC50 in each cell line (2 μM in Hela cells), indicating that the nuclear-targeting moiety assists the transcription factor in reaching its target and imparts enhanced activity.
The covalent protein dimers interfere with MYC-driven gene expression, as determined by RNA-sequencing (RNA-seq) and gene set enrichment analysis (GSEA). To evaluate whether the compounds' bioactivity is related to the suppression of MYC-driven expression, RNA-seq was performed on A549 cells treated with 4. Compared to the control cells, downregulation of 431 and upregulation of 297 genes was observed, indicating that the covalent protein dimers have an effect on gene expression (
Cells were plated at 5,000 cells/well in a 96-well plate the day before the experiment. Covalent protein dimers were prepared at varying concentrations in complete media and transferred to the plate. Cells were incubated at 37° C. and 5% CO2 for 72 h and cell proliferation was measured using the CellTiter-Glo assay quantified by luminescence.
In a 6 well plate, 125,000 A549 cells were plated into each well. The following day, the cells were treated with 4 (12.5 μM) in F12K media supplemented with 10% FBS and 1% pen/strep and incubated for 72 h. RNA was isolated using the Qiagen RNeasy Plus Mini Kit (74136) followed by DNAse treatment (AM1906). KAPAHyperRiboErase libraries were prepared and sequenced on a Hi-seq 2500 instrument. Reads from sequencing were aligned using HISAT2 htseq-count function. Differential gene expression analysis between treated and control cells was performed using DESEQ2 package in R on raw aligned read counts. The differentially expressed genes were ranked by their log2FC and adjusted p-value. Pre-ranked Gene Set Enrichment Analysis (GSEA) was performed using gene sets in Molecular Signatures Database (MSigBD) to identify MYC-target gene sets.
Stepwise automated fast-flow solid-phase synthesis (as described in Example 1) enabled rapid high-fidelity synthesis of Max (10), Myc (11), and Omomyc (12) analogs (83 to 91 residues in length;
The three synthetic analogs 10, 11, and 12 can form non-covalent dimers and bind to the target E-box DNA (5′-CCGGCTGACACGTGGTATTAAT-3′). The DNA-binding activity of 10, 11, and 12 toward the canonical E-box sequence was determined by combining the analogs in all possible binary combinations (Max+Max, Myc+Myc, Omomyc+Omomyc, Myc+Max, Omomyc+Max, and Omomyc+Myc (
Bifunctional palladium oxidative addition complexes (OACs) enabled on-demand synthesis of homo- and heterodimeric analogs of the proteins 10, 11, and 12 to generate all possible covalent dimeric combinations. The dimerization strategy is shown in
To prepare the heterodimeric analogs, a two-step procedure was used by isolating the intermediate protein-OACs. The proteins 10, 11, and 12 were reacted with five equivalents of Pd OAC at room temperature for 60 min (
The covalent protein dimers exhibited α-helical character and displayed higher thermal stability compared to the monomeric analogs. The folding and stability of the dimeric analogs (13, 14, 15, 16, 17, and 18) was characterized via circular dichroism (CD) spectroscopy (see Example 2 for protocol). Strong double minima at 207 and 222 nm indicate an α-helical character of the dimeric analogs (
To a 1.5 mL Eppendorf tube was added Protein-Cys monomer (300 μL, 10.0 mg/mL, 1.0 equiv) as a solution in 20 mM Tris, 150 mM NaCl (pH 7.5), 234 μL 20 mM Tris, 150 mM NaCl (pH 7.5), 30.5 μL DMF and Pd OAC 4 (28.5 μL, 10.0 mg/mL, 1.0 equiv) as a solution in DMF (titrated over one minute). The final reaction concentrations of the major reaction components were the following: 2 (500 μM); 4 (500 μM). The Eppendorf tube was closed, vortexed, and incubated at room temperature for 60 min. A small aliquot was taken from the reaction mixture for analysis by SDS-PAGE. Finally, the reaction was quenched by DTT (10 μl, 1 M in H2O) and kept at room temperature for 5 min, then purified by RP-HPLC.
To a Falcon 15 ml Conical Centrifuge Tube was added Protein monomer (9.0 mL, 1.1 mg/ml, 1.0 equiv) as a solution in 20 mM Tris, 150 mM NaCl (pH 7.5), and Pd OAC (1.0 mL, 4.8 mg/mL, 5.0 equiv) as a solution in DMF. The final reaction concentrations of the major reaction components were the following: 10 (100 μM); Pd OAc (500 μM). The Falcon Tube was closed vortexed and incubated at room temperature for 30 min. A small aliquot was taken from the reaction mixture for analysis by LC-MS. Finally, the reaction was purified by RP-HPLC.
To a 5.0 mL Eppendorf tube was added protein-OAC (500 μL, 6.0 mg/mL, 1.0 equiv) as a solution in 20 mM Tris, 150 mM NaCl (pH 7.5), 260 μl 20 mM Tris, 150 mM NaCl buffer (pH 7.5), 185 μl DMF, and protein-Cys monomer (905 μl, 6.0 mg/ml, 2.0 equiv) as a solution in 20 mM Tris, 150 mM NaCl buffer (pH 7.5). The final reaction concentrations of the major reaction components were the following: protein-OAC (150 μM); protein-Cys (300 μM). The Eppendorf tube was closed, vortexed and incubated at room temperature for 60 min. A small aliquot was taken from the reaction mixture for analysis by SDS-PAGE. Finally, the reaction was quenched by DTT (10 μl, 1 M in H2O) and kept at room temperature for 5 min, then purified by RP-HPLC.
The S-aryl crosslinked protein dimers displayed DNA-binding activity to the E-box sequence. By EMSA, DNA association of Max-Max 14, Myc-Max 16, and Omomyc-Max 17 was observed (
Cell-based studies revealed that the Max-Max 14 covalent protein dimer is intrinsically cell-permeable. To study Max-Max 14 bioactivity, the cross-coupling reaction was scaled up to generate ˜10 mg pure material for cellular studies. To assess the cell permeability, a Max-Max analog labeled with a single carboxytetramethylrhodamine (TAMRA) fluorophore (TAMRA-Max-Max (19) was prepared. Next, the cellular uptake of TAMRA-Max-Max 19 at varying concentrations was determined via flow-cytometry (see Example 3 for protocols). It was found that treatment with dimer 19 produced a dose-dependent increase in fluorescence, indicating that the dimer is taken up into cells (
In addition to entering cells, Max-Max 14 also inhibits the proliferation of Myc-dependent cancer cell lines. In some cancer cell lines, such as HeLa, high levels of Myc drive robust cell proliferation. Covalent dimer 14 was tested in in Hela cells, which contain high levels of Myc, and cell proliferation was measured after 72 h. Covalent dimer 14 was found to inhibit HeLa cell proliferation in a dose-dependent manner with an EC50 of 6 μM. The EC50 of Max-Max 14 is in line with recent studies reporting small molecules for stabilizing endogenous Max dimer in cancer cell lines. Remarkably, in addition to its cell permeability, Max-Max 14 has comparable activity to small molecule-based inhibitors for Myc. Max-Max 14 was also found to inhibit the proliferation of lung adenocarcinoma cells A549 and H441 with EC50 of 19 μM for both. Both of these lung cancer cell lines are known to have lower Myc levels compared to HeLa, which might explain the lower antiproliferative effect of Max-Max 14 in these cells assuming equivalent cell penetration. Taken together, these experiments suggest that Max-Max 14 enters the cells and inhibits cancer cell proliferation potentially by occupying the E-box site and blocking Myc-dependent gene transcription.
RNA-sequencing analysis revealed Max-Max 14 selectively downregulates Myc-target genes in cancer cells. Myc is known to drive cell proliferation by triggering the expression of pro-proliferative genes through binding to the E-box DNA sequences. To assess the antiproliferative activity of Max-Max 14 through regulating Myc-driven genes, lung adenocarcinoma cells A549 were treated with Max-Max 14 for 72 h, and the RNA was extracted for RNA-sequencing analysis (see Example 4 for protocol). It was found that 14 directly interferes with gene transcription by downregulating 160 genes and upregulating 70 genes (
Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including without limitation all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety.
1. Dawson, P. E., Muir, T. W., Clark-Lewis, I. & Kent, S. B. H. Synthesis of proteins by native chemical ligation. Science (80-.). 266, 776 (1994).
2. Bode, J. W., Fox, R. M. & Baucom, K. D. Chemoselective amide ligations by decarboxylative condensations of N-alkylhydroxylamines and α-ketoacids. Angew. Chemie-Int. Ed. 45, 1248-1252 (2006).
3. Premdjee, B., Andersen, A. S., Larance, M., Conde-Frieboes, K. W. & Payne, R. J. Chemical Synthesis of Phosphorylated Insulin-like Growth Factor Binding Protein 2. J. Am. Chem. Soc. 143, 5336-5342 (2021).
4. Agouridas, V. et al. Native Chemical Ligation and Extended Methods: Mechanisms, Catalysis, Scope, and Limitations. Chem. Rev. 119, (2019).
5. Conibear, A. C., Watson, E. E., Payne, R. J. & Becker, C. F. W. Native chemical ligation in protein synthesis and semi-synthesis. Chem. Soc. Rev. 47, 9046-9068 (2018).
6. Bondalapati, S., Jbara, M. & Brik, A. Expanding the chemical toolbox for the synthesis of large and uniquely modified proteins. Nat. Chem. 8, 407-418 (2016).
7. Bertolini, M. et al. Interactions between nascent proteins translated by adjacent ribosomes drive homomer assembly. Science (80-.). 371, 57-64 (2021).
8. Shiber, A. et al. Cotranslational assembly of protein complexes in eukaryotes revealed by ribosome profiling. Nature 561, 268-272 (2018).
9. Meyer, N. & Penn, L. Z. Reflecting on 25 years with MYC. Nat. Rev. Cancer 8, 976-990 (2008).
10. Blackwell, T., Kretzner, L., Eisenman, R., Weintraub, H. & Blackwood, E. Sequence-specific DNA binding by the c-Myc protein. Science (80-.). 250, 1149-1151 (2006).
11. Blackwood, E. M. & Eisenman, R. N. Max: A Helix-Loop-Helix Zipper Protein That Complex with Myc. Science (80-.). 251, 1211-1217 (1991).
12. Ferré-D′Amaré, A. R., Prendergast, G. C., Ziff, E. B. & Burley, S. K. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain. Nature 363, 38-45 (1993).
13. Chen, H., Liu, H. & Qing, G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct. Target. Ther. 3, 1-7 (2018).
14. Kalkat, M. et al. MYC deregulation in primary human cancers. Genes (Basel). 8, 2-30 (2017).
15. Rahl, P. B. et al. Transcriptional Amplification in Tumor Cells with Elevated c-Myc. (2012). doi: 10.1016/j.cell.2012.08.026
16. Lee, T. I. & Young, R. A. Transcriptional regulation and its misregulation in disease. Cell 152, 1237-1251 (2013).
17. Fletcher, S. & Prochownik, E. V. Small-molecule inhibitors of the Myc oncoprotein. Biochim. Biophys. Acta—Gene Regul. Mech. 1849, 525-543 (2015).
18. Boike, L. et al. Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC. Cell Chem. Biol. 1-10 (2020). doi: 10.1016/j.chembiol.2020.09.001
19. Han, H. et al. Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer Cell 36, 483-497.e15 (2019).
20. Koehler, A. N. A complex task? Direct modulation of transcription factors with small molecules. Curr. Opin. Chem. Biol. 14, 331-340 (2010).
21. Ulasov, A. V., Rosenkranz, A. A. & Sobolev, A. S. Transcription factors: Time to deliver. J. Control. Release 269, 24-35 (2018).
22. Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P. & Mason, J. M. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. Mol. Cancer 20, 1-18 (2021).
23. Struntz, N. B. et al. Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription. Cell Chem. Biol. 26, 711-723.e14 (2019).
24. Soucek, L. et al. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 17, 2463-2472 (1998).
25. Massó-Vallés, D. & Soucek, L. Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc. Cells 9, 883 (2020).
26. Beaulieu, M. E. et al. Intrinsic cell-penetrating activity propels omomyc from proof of concept to viable anti-myc therapy. Sci. Transl. Med. 11, 1-14 (2019).
27. Demma, M. J. et al. Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene. Mol. Cell. Biol. 39, 1-27 (2019).
28. Lobba, M. J. et al. Site-Specific Bioconjugation through Enzyme-Catalyzed Tyrosine—Cysteine Bond Formation. ACS Cent. Sci. (2020). doi: 10.1021/acscentsci.0c00940
29. Dhanjee, H. H. et al. Protein-Protein Cross-Coupling via Palladium-Protein Oxidative Addition Complexes from Cysteine Residues. J. Am. Chem. Soc. 142, 9124-9129 (2020).
30. Kumar, K. S. A., Spasser, L., Erlich, L. A., Bavikar, S. N. & Brik, A. Total chemical synthesis of di-ubiquitin chains. Angew. Chemie—Int. Ed. 49, 9126-9131 (2010).
31. Chatterjee, C., McGinty, R. K., Pellois, J.-P. & Muir, T. W. Auxiliary-Mediated Site-Specific Peptide Ubiquitylation. Angew. Chemie 119, 2872-2876 (2007).
32. Ajish Kumar, K. S., Haj-Yahya, M., Olschewski, D., Lashuel, H. A. & Brik, A. 32. Highly efficient and chemoselective peptide ubiquitylation. Angew. Chemie—Int. Ed. 48, 8090-8094 (2009).
33. Fottner, M. et al. Site-specific ubiquitylation and SUMOylation using genetic-code expansion and sortase. Nat. Chem. Biol. 15, 276-284 (2019).
34. Sui, X. et al. Development and application of ubiquitin-based chemical probes. Chem. Sci. 11, 12633-12646 (2020).
35. Geurink, P. P., El Oualid, F., Jonker, A., Hameed, D. S. & Ovaa, H. A General Chemical Ligation Approach Towards Isopeptide-Linked Ubiquitin and Ubiquitin-Like Assay Reagents. ChemBioChem 13, 293-297 (2012).
36. Kulkarni, S. S., Sayers, J., Premdjee, B. & Payne, R. J. Rapid and efficient protein synthesis through expansion of the native chemical ligation concept. Nat. Rev. Chem. 2, 1-17 (2020).
37. Pan, M. et al. Quasi-Racemic X-ray Structures of K27-Linked Ubiquitin Chains Prepared by Total Chemical Synthesis. J. Am. Chem. Soc. 138, 7429-7435 (2016).
38. Torbeev, V. Y. et al. Protein conformational dynamics in the mechanism of HIV-1 protease catalysis. Proc. Natl. Acad. Sci. U. S. A. 108, 20982-20987 (2011).
39. Nair, S. K. & Burley, S. K. X-ray structures of Myc-Max and Mad-Max recognizing DNA: Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112, 193-205 (2003).
40. Canne, L. E., Ferré-D′Amaré, A. R., Burley, S. K. & Kent, S. B. H. Total Chemical Synthesis of a Unique Transcription Factor-Related Protein: cMyc—Max. J. Am. Chem. Soc. 117, 2998-3007 (1995).
41. Mijalis, A. J. et al. A fully automated flow-based approach for accelerated peptide synthesis. Nat. Chem. Biol. 13, 464-466 (2017).
42. Hartrampf, N. et al. Synthesis of proteins by automated flow chemistry. Science 368, 980-987 (2020).
43. Palmacci, E. R., Plante, O. J., Hewitt, M. C. & Seeberger, P. H. Automated Synthesis of Oligosaccharides. Science (80-.). 291, 1523 (2001).
44. Schissel, C. et al. Interpretable Deep Learning for De Novo Design of Cell-Penetrating Abiotic Polymers. (2020). doi: 10.1101/2020.04.10.036566
45. Fadzen, C. M. et al. Chimeras of Cell-Penetrating Peptides Demonstrate Synergistic Improvement in Antisense Efficacy. Biochemistry 58, 3980-3989 (2019).
46. Wang, E. et al. Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers. Oncogene 38, 140-150 (2019).
47. Fukazawa, T. et al. Inhibition of myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc. Anticancer Res. 30, 4193-4200 (2010).
48. Spiegel, J., Cromm, P. M., Zimmermann, G., Grossmann, T. N. & Waldmann, H. Small-molecule modulation of Ras signaling. Nat. Chem. Biol. 10, 613-622 (2014).
49. Johnson, C. D. et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 67, 7713-7722 (2007).
50. Blackwood, E. M. & Eisenman, R. N. Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science (80-.). 251, 1211-1217 (1991).
51. Amati, B. et al. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature 359, 423-426 (1992).
52. Hu, J., Banerjee, A. & Goss, D. J. Assembly of b/HLH/z proteins c-Myc, Max, and Mad1 with cognate DNA: Importance of protein-protein and protein-DNA interactions. Biochemistry 44, 11855-11863 (2005).
53. Montagne, M. et al. The max b-HLH-LZ can transduce into cells and inhibit c-Myc transcriptional activities. PLOS One 7, 2-10 (2012).
54. Demma, M. J. et al. Inhibition of Myc transcriptional activity by a mini-protein based upon Mxd1. FEBS Lett. 594, 1467-1476 (2020).
This application is a U.S. National Stage filing under 35 U.S.C. § 371 of International Patent Application No. PCT/US2022/033920, filed Jun. 17, 2022, which claims the priority benefit of U.S. Provisional Patent Application Ser. No. 63/213,024, filed Jun. 21, 2021. The entirety of these applications are hereby incorporated by reference.
This invention was made with government support under Grant No. VR 2017-00372 awarded by the Swedish Research Council; Grant No. PO 2413/1-1, awarded by Deutsche Forschungsgemeinschaft; Grant No. 1122374 awarded by the National Science Foundation Graduate Research Fellowship; and Grant No. 174530 awarded by the National Science Foundation Graduate Research Fellowship. The government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2022/033920 | 6/17/2022 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63213024 | Jun 2021 | US |
